Categories: News

Spago Nanomedical Presents its Q1 Report and Provides Company Update

LUND, SE / ACCESSWIRE / April 20, 2022 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)

Spago Nanomedical AB (publ) publishes its interim report for January-March 2022 on Tuesday, 27 April, 2022 at 08.00 CEST. On the same day, at 13.00 CEST, the company management presents the report and also provides an update on the company’s operations. The presentation will be held in English.

The presentation will be held at Penser Bank AB, Apelbergsgatan 27, Stockholm, and can be followed digitally, live and afterwards via the following link: https://youtu.be/pqfdg9mqf0E.

Registration for participation at Penser Bank is made to http://enews.penser.se/public/event/RegistrationForm/43435C427041465A4B7840.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se.

Attachments

Spago Nanomedical presents its Q1 report and provides company update

SOURCE: Spago Nanomedical

View source version on accesswire.com:
https://www.accesswire.com/698132/Spago-Nanomedical-Presents-its-Q1-Report-and-Provides-Company-Update

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

13 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

16 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

16 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

16 hours ago